Do you want to read an article? Please log in or register.
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
Skin Cancer
Related content
Skin Cancer
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Eur J Cancer
Kött J, Zell T, Zimmermann N, Rünger A, Smit DJ, Abeck F, Geidel G, Hansen-Abeck I, Heidrich I, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, Zimmer L, Livingstone E, Wasielewski IV, Mohr P, Meier F, Haferkamp S, Drexler K, Herbst R, Kellner I, Utikal J, Wohlfeil SA, Pföhler C, Adam L, Terheyden P, Ulrich J, Meiss F, Möbes M, Welzel J, Schilling B, Ziller F, Kaatz M, Kreuter A, Sindrilaru A, Dippel E, Sachse M, Weishaupt C, Hüning S, Heinzerling L, Loquai C, Schley G, Gambichler T, Löffler H, Grabbe S, Schultz E, Devereux N, Hassel JC, Simon JC, Raap U, Assaf C, Klemke CD, Sunderkötter C, Hofmann SC, Wenk S, Tronnier M, Thies S, Heppt MV, Eggermont A, Schulze HJ, Zouboulis CC, Tüting T, Bauer AT, Schneider SW, Gebhardt C
doi: 10.1016/j.ejca.2024.115159
ASCO 2024
Multiple Myeloma (MM)
DREAMM-7: Belantamab mafodotin plus Vd improved survival and response rates in patients with RRMM, including those with poor prognostic features
ESMO 2024
Breast Cancer
DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases
ESMO 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
Skin Cancer
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study
Eur J Cancer
Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S
doi: 10.1016/j.ejca.2024.115099
Lung, Respiratory and Thoracic Cancer
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
J Thorac Oncol
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT
doi: 10.1016/j.jtho.2024.09.1443
ESMO 2024
Skin Cancer
CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma
Skin Cancer
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
Eur J Cancer
Pires da Silva I, Li I, Ugurel S, Serra-Bellver P, Andhale A, Burnette H, Aya F, Conway JW, Braden J, Carlino MS, Menzies AM, Weichenthal M, Mohr P, Gutzmer R, Arance AM, Johnson DB, Lorigan P, Schadendorf D, Lo SN, Long GV
doi: 10.1016/j.ejca.2024.114101
COMMENTED
Breast Cancer
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA
doi: 10.1016/j.annonc.2024.08.2347